AI health assistants may be used to surface clinical trials earlier in patient journeys, and advertising inside conversational AI is best understood as the next logical step in that same progression.
- Informed Consent Isn't Broken — But It's Barely Working
- Pharma Procurement Can Make Or Break Startups: Let's Help Mature Our Future Partners To Secure Innovation
- Becoming A Backbone Therapy: Lessons Learned With Actuate Therapeutics
- Building Patient Trust In Research Through Connection Driven-Transparency
- How To Lead A Moonshot Collaboration: Lessons From Over A Decade Of Competitors Working Together
- Patient Trust In Pharma Is Low; Here's How To Rebuild It
- Why Dr. Robert Califf Isn't Pulling His Punches Anymore
GUEST COLUMNISTS
-
![Healthcare Questions-GettyImages-2193936936]( "Patient Trust In Pharma Is Low; Here's How To Rebuild It")
Patient Trust In Pharma Is Low; Here's How To Rebuild ItCISCRP's Annick de Bruin and Shalome Sine provide strategies for building patient trust based on the findings from their Perceptions & Insights Study.
-
![American Flag-GettyImages-2256012795]( "The U.S. Trial Advantage Is Eroding")
The U.S. Trial Advantage Is ErodingOnce the go-to location for trials, the U.S. is now seeing competition from APAC, driven by political, economic, and workforce pressures domestically and rapid growth abroad.
-
![Machine learning, ai, aertificial intelligence-GettyImages-2216092983]( "Making AI Safety Routine: How Sites And Sponsors Can Continuously Monitor Clinical AI")
Making AI Safety Routine: How Sites And Sponsors Can Continuously Monitor Clinical AILearn why the next frontier in AI governance will involve real-time surveillance of algorithmic performance across institutions with guidance from Akshaya Bhagavathula and Michelle A. Williams.
-
![Lessons Learned-GettyImages-835037356]( "Want To Optimize Clinical Project Team Performance? Try This Formal 'Lessons Learned' Process")
Want To Optimize Clinical Project Team Performance? Try This Formal 'Lessons Learned' ProcessLearn how a formal "lessons learned" process can help teams work collaboratively with open, honest, and timely communication to reach thoughtful decisions that lead to on-time, on-budget, and inspection-ready trials.
-
![Number 4-GettyImages-1458365060]( "4 Factors Changing The Way CRAs Monitor Trials")
4 Factors Changing The Way CRAs Monitor TrialsThe way CRAs monitor is about to change. Regeneron's Patrick Floody discusses these four factors that will influence it.
-
![Business Quality Assurance and Compliance-GettyImages-2225358412]( "How Can AI Change Computerized System Validation?")
How Can AI Change Computerized System Validation?Learn how AI technologies are changing the computer system validation (CSV) landscape and what you need to understand about this transformation.
-
![bechtel getz series article 2]( "Too Little Info, Too Much Time Wasted: Feasibility Challenges For Sites")
Too Little Info, Too Much Time Wasted: Feasibility Challenges For SitesIncomplete protocols, lengthy sponsor decision timelines, and uncompensated work plague clinical research sites. Learn why these issues exist and how to address them alongside experts from SCRS and Tufts CSDD.
-
![digital platform, artificial intelligence, machine learning, processing for mental health-GettyImages-2234202465]( "Will New AI Health Assistants Suggest Clinical Trials To Inquiring Patients?")
Will New AI Health Assistants Suggest Clinical Trials To Inquiring Patients?New AI health assistants are now doing even more to help patients make sense of symptoms, diagnoses, and treatment options. What does that mean for the discoverability of clinical trials?
CLINICAL TRIAL WHITE PAPERS
-
![diversity - equality iStock-1303294233]( "Practical Strategies For Diverse Trial Recruitment")
Practical Strategies For Diverse Trial RecruitmentThe clock is ticking on the requirement for pharmaceutical companies to include FDA-mandated diversity action plans for pivotal studies in clinical trials.
-
Clinical Trial Disclosure Noncompliance: What Is Its Impact On Pharma M&As?10/20/2025
Noncompliance with clinical trial disclosure regulations can jeopardize M&A deals. Understanding FDA and SEC requirements is critical to avoid red flags during due diligence.
-
Designing More Representative Trials Through Strategic Planning5/28/2025
Strategic planning for representative clinical trials improves outcomes, regulatory alignment, recruitment efficiency, and commercial value by ensuring study populations mirror real-world patients.
-
Key AI Trial Insights From Regulators And Consultants4/4/2025
AI’s transformative impact promises more efficient, cost-effective, and successful clinical trials across the pharmaceutical landscape.
-
Digital Endpoint Resource Guide: Obesity And Related Metabolic Disorders8/15/2024
Explore how digital health technologies can enhance obesity treatment by providing critical insights beyond weight loss.
-
Antibody-Drug Conjugates: 'Magic Bullets' Become Reality2/19/2025
Cancer therapy has evolved from potent chemotherapy to targeted biological therapy, including antibody-drug conjugates (ADCs). Learn more about ADCs’ makeup, mechanisms, and the development landscape.
CLINICAL TRIAL APP NOTES & CASE STUDIES
-
How To Recruit 236 Patients In An Osteoarthritis Study On Time During The Peak Of The Pandemic7/23/2024
A leading Eastern European contract research organization completed the recruitment of 236 subjects in a Phase 3 osteoarthritis study for Handok Inc. despite hurdles caused by the COVID-19 pandemic.
-
RTSM: Randomization And Cohort Management, IP Inventory Management4/17/2024
Signant’s SmartSignals® RTSM solution helped an innovative biopharmaceutical company secure an FDA Orphan Drug designation for its cardiomyopathy drug.
-
Automated Trial Monitoring Workflows Make A Lean Team More Efficient1/7/2026
A pharmaceutical therapy developer was looking to automate reports, confirmation letters, and follow-up letters. See what happened when they adopted a cloud-based solution for end-to-end trial management.
-
Accelerating Early Phase Oncology Study Development4/17/2025
Explore a close collaboration to co-develop a comprehensive, adaptive protocol designed to support key decisions across multiple trial phases for an innovative cancer therapy.
-
U.S. Renal Care Achieves 75% Site Adoption Of eConsent5/1/2024
By dispelling prevalent misconceptions regarding participant age, cost, and complexity, see how this platform emerged as a versatile, rapid, and effective solution tailored to the unique needs of the elderly renal care population.
-
Ergomed's Solutions To The Challenges of Oncology Trials4/15/2025
Explore a pivotal Phase III global clinical trial investigating neoadjuvant immunotherapy for locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).
NEWSLETTER ARCHIVE
- 02.10.26 -- 3 Clinical Research Attorneys Talk 2026 Trends
- 02.09.26 -- Why The EU Biotech Act Matters To The U.S.: A Clinical Perspective
- 02.06.26 -- 4 Factors Changing The Way CRAs Monitor Trials
- 02.06.26 -- Pave The Way To Clinical Trial Operation Success
- 02.05.26 -- What To Watch For In The 2026 Clinical Trial Landscape
RECRUITMENT AND DIVERSITY
This section includes some helpful resources regarding patient recruitment and diversity in clinical trials, including this link to the FDA's guidance on diversity action plans.
-
![advertising on social media-GettyImages-2201068162]( "What ChatGPT Ads Will Really Mean For Clinical Trials")
AI health assistants may be used to surface clinical trials earlier in patient journeys, and advertising inside conversational AI is best understood as the next logical step in that same progression.
-
![Medical examination of woman using ultrasound equipment of liver kidneys-GettyImages-1482783655]( "Building Patient Trust In Research Through Connection Driven-Transparency")
The question is not whether trust matters but how industry, sponsors, and investigators can bridge the trust gap to drive patient participation.
-
![Healthcare Questions-GettyImages-2193936936]( "Patient Trust In Pharma Is Low; Here's How To Rebuild It")
CISCRP's Annick de Bruin and Shalome Sine provide strategies for building patient trust based on the findings from their Perceptions & Insights Study.
FOCUS ON PATIENTS
-
![Fun while washing hands-GettyImages-2217454730]( "The FDA Calls For Culturally-Informed Research, But What Do We Understand About The Sikh Community?")
Despite the size and visibility of the community — and the call for diverse patient research — there remains a gap in available health data specific to the Sikh community in the U.S.
-
![Manager checking expiration dates in drugstore-GettyImages-1666055443]( "The Key Role Of Clinical Supply Teams In Patient Centricity Efforts")
Clinical supply decisions shape patient access, safety, and trial success. From logistics to procurement, patient-centric supply can accelerate therapies or quietly delay them.
-
![Medical examination of woman using ultrasound equipment of liver kidneys-GettyImages-1482783655]( "Building Patient Trust In Research Through Connection Driven-Transparency")
The question is not whether trust matters but how industry, sponsors, and investigators can bridge the trust gap to drive patient participation.
